Wall Street analyst has provided a review for the NA company today, but retained the same rating on the stock. Analyst Matt Bottomley from Canaccord Genuity rated MPX Bioceutical Corporation (CNQX: MPX) a Buy, setting a C$1.15 price target.

According to TipRanks.com, Bottomley is ranked #366 out of 4757 analysts.

MPX Bioceutical Corporation has an analyst consensus of Moderate Buy, with a price target consensus of C$1.28.

Based on MPX Bioceutical Corporation’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of C$4.48 million and GAAP net loss of C$9.23 million. In comparison, last year the company earned revenue of C$0 and had a GAAP net loss of C$552.7K.

MPX Bioceutical Corp. provides management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services. It offers financial and business assistance to emerging corporations, which includes pharmaceutical, medical and biotechnology industries.